Luca Tosoni

Udine, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

To transplant or not to transplant after CAR-T: that is the question!

To transplant or not to transplant after CAR-T: that is the question!

Journal: Recenti progressi in medicina
Published: January 22, 2026

High JAK2V617F allele burden in low-risk PV: an additional recommendation to start "early" cytoreduction? Results from a multicentric study.

High JAK2V617F allele burden in low-risk PV: an additional recommendation to start "early" cytoreduction? Results from a multicentric study.

Journal: Leukemia research
Published: July 24, 2025

Intensification of Treosulfan-Fludarabine Conditioning With Thiotepa Exhibited Effectiveness and Tolerability in Older or Comorbid Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With Active Myeloid Neoplasm: A Real-world Study.

Intensification of Treosulfan-Fludarabine Conditioning With Thiotepa Exhibited Effectiveness and Tolerability in Older or Comorbid Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With Active Myeloid Neoplasm: A Real-world Study.

Journal: Transplantation direct
Published: July 17, 2025

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Journal: Cancer
Published: May 05, 2025

New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers.

New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers.

Journal: Journal of clinical medicine
Published: December 13, 2024

The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.

The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.

Journal: Blood cancer journal
Published: July 17, 2024

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

Journal: Cancer
Published: April 19, 2024

Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.

Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.

Journal: Annals of hematology
Published: December 29, 2023

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.

Journal: Blood cancer journal
Published: December 08, 2023

Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.

Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.

Journal: Annals of hematology
Published: November 12, 2023

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

Journal: Annals of hematology
Published: March 06, 2023
Showing 1-11 of 11

Last Updated: 09/26/2026